NasdaqGS:MEDP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. More Details


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Medpace Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MEDP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.3%

MEDP

2.0%

US Life Sciences

1.3%

US Market


1 Year Return

30.8%

MEDP

36.0%

US Life Sciences

15.8%

US Market

Return vs Industry: MEDP underperformed the US Life Sciences industry which returned 34.2% over the past year.

Return vs Market: MEDP exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

MEDPIndustryMarket
7 Day-0.3%2.0%1.3%
30 Day-14.0%-1.1%-4.1%
90 Day18.2%11.8%8.4%
1 Year30.8%30.8%36.2%36.0%18.4%15.8%
3 Year234.6%234.6%87.1%86.0%38.2%29.0%
5 Yearn/a185.5%181.8%84.9%64.0%

Price Volatility Vs. Market

How volatile is Medpace Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medpace Holdings undervalued compared to its fair value and its price relative to the market?

36.97x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: MEDP ($109.91) is trading above our estimate of fair value ($101.86)

Significantly Below Fair Value: MEDP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MEDP is good value based on its PE Ratio (37x) compared to the US Life Sciences industry average (41.7x).

PE vs Market: MEDP is poor value based on its PE Ratio (37x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: MEDP is poor value based on its PEG Ratio (2.4x)


Price to Book Ratio

PB vs Industry: MEDP is good value based on its PB Ratio (5.2x) compared to the US Life Sciences industry average (6.1x).


Next Steps

Future Growth

How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

15.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDP's forecast earnings growth (15.6% per year) is above the savings rate (2.2%).

Earnings vs Market: MEDP's earnings (15.6% per year) are forecast to grow slower than the US market (22.9% per year).

High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEDP's revenue (15.1% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MEDP's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MEDP's Return on Equity is forecast to be low in 3 years time (19.6%).


Next Steps

Past Performance

How has Medpace Holdings performed over the past 5 years?

56.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MEDP has high quality earnings.

Growing Profit Margin: MEDP's current net profit margins (12.1%) are higher than last year (11.2%).


Past Earnings Growth Analysis

Earnings Trend: MEDP has become profitable over the past 5 years, growing earnings by 56.7% per year.

Accelerating Growth: MEDP's earnings growth over the past year (20.4%) is below its 5-year average (56.7% per year).

Earnings vs Industry: MEDP earnings growth over the past year (20.4%) exceeded the Life Sciences industry 14.9%.


Return on Equity

High ROE: MEDP's Return on Equity (14.5%) is considered low.


Next Steps

Financial Health

How is Medpace Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MEDP's short term assets ($319.1M) do not cover its short term liabilities ($338.0M).

Long Term Liabilities: MEDP's short term assets ($319.1M) exceed its long term liabilities ($146.1M).


Debt to Equity History and Analysis

Debt Level: MEDP is debt free.

Reducing Debt: MEDP has no debt compared to 5 years ago when its debt to equity ratio was 106.8%.

Debt Coverage: MEDP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MEDP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Medpace Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average management tenure


CEO

August Troendle (64 yo)

28.17yrs

Tenure

US$7,712,835

Compensation

Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer and President at Medpace Holdings, Inc. since July 1992. Dr. Troendle founded Medpace Holdings, Inc. in July 1992. He founded ...


CEO Compensation Analysis

Compensation vs Market: August's total compensation ($USD7.71M) is above average for companies of similar size in the US market ($USD5.75M).

Compensation vs Earnings: August's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
August Troendle
Chairman28.17yrsUS$7.71m21.01%
$ 800.9m
Jesse Geiger
CFO & COO of Laboratory Operations9.5yrsUS$1.88m0.018%
$ 691.0k
Susan Burwig
Executive Vice President of Operations3.67yrsUS$2.43m0.11%
$ 4.2m
Stephen Ewald
Chief Compliance Officer0.58yrUS$1.25m0.0095%
$ 361.3k
Todd Meyers
Vice President of Business Development & Marketingno datano datano data
Weimin Gai
Senior Vice President of Biometricsno datano datano data
Daniel O'Leary
Senior Vice President of Medical Departmentno datano datano data
John Wynne
Senior Vice President of Commercial Operations & Clinical Pharmacology Unitno datano datano data
Kevin Brady
Executive Director of Financeno datano datano data

6.6yrs

Average Tenure

54yo

Average Age

Experienced Management: MEDP's management team is seasoned and experienced (6.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
August Troendle
Chairman28.17yrsUS$7.71m21.01%
$ 800.9m
Fred Davenport
Lead Independent Director1.92yrsUS$142.60k0.0043%
$ 162.4k
Cornelius McCarthy
Independent Director2.08yrsUS$135.10k0%
$ 0
Thomas King
Independent Director0.92yrUS$60.29k0%
$ 0
Robert Kraft
Independent Director4.17yrsUS$144.99k0%
$ 0
Brian Carley
Independent Director4.17yrsUS$149.99k0%
$ 0
Ashley Keating
Independent Director1.33yrsUS$114.94k0%
$ 0

2.1yrs

Average Tenure

62yo

Average Age

Experienced Board: MEDP's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MEDP insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medpace Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medpace Holdings, Inc.
  • Ticker: MEDP
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.812b
  • Shares outstanding: 35.21m
  • Website: https://www.medpace.com

Number of Employees


Location

  • Medpace Holdings, Inc.
  • 5375 Medpace Way
  • Cincinnati
  • Ohio
  • 45227
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
01PDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2016
MEDPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2016
MEDP *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNAug 2016

Biography

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industrie ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 23:50
End of Day Share Price2020/09/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.